Skip to main content
OpenTrials
Completed

NCT Number: NCT04057937

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP. This study also will evaluate the safety and tolerability of apremilast in Japanese subjects with PPP.CC-10004-PPP-001 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2 study of apremilast in Japanese subjects with PPP and inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations.

The placebo-controlled period will be 16 weeks and patients will receive apremilast or placebo. After the 16-week placebo-controlled period, all subjects will receive apremilast for 16 weeks. All subjects will have their final study visit 4 weeks after stopping apremilast treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Palmoplantaris Pustulosis Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Research Site, Ichinomiya, Aichi-ken, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  • Subject has a diagnosis of Palmoplantar Pustulosis with or without pustulotic arthro-osteitis (PAO) for at least 24 weeks before screening.
  • Subject has a total score of PPPASI: ≥ 12 at screening and baseline.
  • Subject has moderate or severe pustules/vesicles on palms or soles (PPPASI severity score: ≥ 2) at screening and baseline.
  • Subject has inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations prior to or at screening.

Exclusion criteria

The presence of any of the following will exclude a subject from enrollment:

  • Subject has a diagnosis of plaque-type psoriasis.
  • Subject has the presence of pustular psoriasis in any part of the body other than the palms and soles.
  • Subject has obvious improvement during screening (≥ 5 PPPASI total score improvement during the screening).
  • Subject has received any procedures for focal infection (e.g, tonsillectomy and dental therapy) within 24 weeks of baseline.
  • Subject has periodontitis obviously requiring treatment at screening.
  • Subject has chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment for a month or more at screening.
  • Subject has evidence of skin conditions of hands and feet that would interfere with evaluations of the effect of study medication.
  • Subject is pregnant or breastfeeding.

Treatment and study plan

Apremilast

Drug

Apremilast

Other names: CC-10004

Placebo

Drug

Placebo

Primary outcomes

  1. Percentage of Participants Who Achieve a PPPASI-50 at Week 16

    Time frame: At Week 16

    PPPASI-50 is defined as >= 50 percent decrease in PPPASI total score from baseline.

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.

Secondary outcomes

  1. Percentage of Participants Who Achieve a PPPASI-50 at All Other Visits in Placebo-controlled Phase

    Time frame: Weeks 2 to 14

    PPPASI-50 is defined as >= 50 percent decrease in PPPASI total score from baseline.

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values at were imputed using non-responder imputation (NRI) as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

  2. Percentage of Participants Who Achieve a PPPASI-75 at Each Visit in Placebo-controlled Phase

    Time frame: Weeks 2 to 16

    PPPASI-75 is defined as >=75 percent decrease in PPPASI total score from baseline.

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

  3. Area Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 16

    Time frame: Baseline to Week 16

    The AUC for PPPASI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method.

    PPPASI is a disease-specific efficacy assessment tool to evaluate 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.

  4. Percent Change From Baseline in PPPASI Total Score by Visit in Placebo-controlled Phase .

    Time frame: Baseline to Week 16

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. A positive change from baseline indicates a worsening of symptoms.

  5. Change From Baseline in PPPASI Total Score at Week 16

    Time frame: Baseline and Week 16

    PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.

  6. AUC for PPSI Total Score From Baseline Through Week 16

    Time frame: Baseline to Week 16

    The AUC for PPSI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease.

  7. Percent Change From Baseline in PPSI Total Score by Visit in Placebo-controlled Phase

    Time frame: Baseline to Week 16

    PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. A positive change from baseline indicates a worsening of symptoms.

  8. Change From Baseline in PPSI Total Score at Week 16

    Time frame: Baseline and Week 16

    PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.

  9. Percentage of Participants Achieving a PGA Score of Clear (0) or Minimal (1) by Visit in Placebo-controlled Phase

    Time frame: Weeks 2 to 16

    The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales:

    0 = Clear

    • = Almost clear/Minimal
    • = Mild
    • = Moderate
    • = Severe
    • = Very severe.

    The percentage of of participants with a post baseline score of 0 or 1 (responders) are reported. Missing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

  10. Percentage of Participants Achieving a PGA Score of 0 or 1 With At Least a 2 Grade Improvement by Visit in Placebo-controlled Phase.

    Time frame: Weeks 2 to 16

    The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales:

    0 = Clear

    • = Almost clear/Minimal
    • = Mild
    • = Moderate
    • = Severe
    • = Very severe.

    The percentage of of participants with at least a 2 grade improvement from baseline (stringent responders) are reported. issing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.

  11. Change From Baseline in Participant VAS Assessment for PPP Symptoms

    Time frame: Baseline and Weeks 2,4,6,8,12,16

    Participants assessed the degree of both pruritus itching and skin discomfort/pain as symptoms on hands and feet caused by PPP on a VAS. Each score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch/pain and the right-hand boundary (100) represents itch/pain as severe as can be imagined by participant.

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Palmoplantar Pustulosis in Japan

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Aug 15, 2019
Registry last updated
Jul 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.